Zymeworks BC Inc [ZYME] stock prices are up 9.03% to $19.68 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ZYME shares have gain 8.37% over the last week, with a monthly amount glided 8.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on October 14, 2025, and kept the price target unchanged to $26. On October 10, 2025, B. Riley Securities initiated with a Buy rating and assigned a price target of $30 on the stock. TD Cowen started tracking the stock assigning a Buy rating. JP Morgan upgraded its rating to a Overweight but $18 remained the price target by the analyst firm on December 16, 2024. Leerink Partners upgraded its rating to Outperform for this stock on November 07, 2024, and upped its price target to $25. In a note dated November 01, 2024, Wells Fargo downgraded an Equal Weight rating on this stock but restated the target price of $12.
The stock price of Zymeworks BC Inc [ZYME] has been fluctuating between $9.03 and $19.98 over the past year. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $19.68 at the most recent close of the market. An investor can expect a potential return of 32.11% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
The Zymeworks BC Inc [NASDAQ:ZYME] reported sales of 134.48M for trailing twelve months, representing a surge of 72.59%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -207.35%, Pretax Profit Margin comes in at -171.28%, and Net Profit Margin reading is -183.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.24 and Total Capital is -0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.67 points at the first support level, and at 17.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.24, and for the 2nd resistance point, it is at 20.79.
Ratios To Look Out For
It’s worth pointing out that Zymeworks BC Inc [NASDAQ:ZYME]’s Current Ratio is 6.94. Further, the Quick Ratio stands at 6.94, while the Cash Ratio is 1.54. Considering the valuation of this stock, the price to sales ratio is 11.03, the price to book ratio is 4.66.
Transactions by insiders
Recent insider trading involved EcoR1 Capital, LLC, Director, that happened on May 15 ’25 when 49502.0 shares were purchased. Director, EcoR1 Capital, LLC completed a deal on May 19 ’25 to buy 5919.0 shares. Meanwhile, Director EcoR1 Capital, LLC bought 73953.0 shares on Apr 16 ’25.
